<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537144</url>
  </required_header>
  <id_info>
    <org_study_id>16-04411-FB</org_study_id>
    <nct_id>NCT03537144</nct_id>
  </id_info>
  <brief_title>Acetaminophen vs Indomethacin in Treating hsPDA</brief_title>
  <official_title>Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if acetaminophen (Tylenol) is as effective as
      indomethacin in closing patent ductus arteriosus in premature infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a randomized, controlled, non-inferiority trial, and we plan to enroll
      premature infants &lt;32 weeks, &lt;1500g, and who are &lt; 21 days of age at Regional One Health,
      LeBonheur Children's Hospital, and Methodist Germantown NICUs in Memphis, TN. A study group
      of 42 patients for each group will be needed to allow a maximum difference of 25% to consider
      non-inferiority in the closure rate between IV acetaminophen and IV indomethacin (with power
      of 80% and alpha of 0.05).2 Our goal will be to enroll 50 infants for each treatment group,
      to help with an expected 20% drop out rate either due to complications or parents removal of
      consent. Dosages: IV acetaminophen 15mg/kg/dose every 6 hours for 12 doses,6 IV indomethacin
      dose will depend on age.IV indomethacin will be given every 12 hours for 3 doses. The infants
      will be eligible for the study after primary attending has made the decision to treat the
      hsPDA. The goal will be 50 infants in the IV acetaminophen group and 50 infants in the IV
      indomethacin group.

      Informed consent will be obtained from the parent after ECHO has been obtained and the
      primary attending has decided to treat PDA in the infant who meets inclusion criteria without
      any of the exclusion criteria. We will use block randomization and stratify by site to
      generate 140 random values of either 0 for acetaminophen or 1 for indomethacin. The goal will
      be 50 infants randomized to acetaminophen group and 50 infants randomized to indomethacin
      group. The numbers will be placed in opaque envelope and opened after consent is obtained.
      The primary team will not be blinded given the different frequencies of administration of
      acetaminophen and indomethacin. The first ECHO will be read by staff pediatric cardiologist.
      A pediatric cardiologist will retrospectively go back and read all ECHOs blinded for
      standardization.

      Prior to induction of treatment, we will record complete blood count (CBC) and complete
      metabolic panel (CMP) with AST/ALT. After treatment, we will record AST/ALT within 48 hours,
      and we will record follow-up ECHO reports that occur within seven days of initiation of
      treatment. The decision to repeat treatment will be left to primary attending's discretion.
      The primary attending will determine any additional medical or surgical treatment if
      indicated. Data regarding ROP, IVH, and BPD will be collected from patient's chart prior to
      discharge.

      Primary outcome will be the rate of successful PDA treatment by ECHO in each group.
      Successful PDA treatment will be defined as no longer meeting ECHO criteria for hsPDA.
      Secondary outcome data will be recorded and include the following: retreatment, surgical
      closure, days on invasive mechanical ventilation, duration of supplemental oxygen
      requirement, respiratory support at 36 weeks post-menstrual age (PMA), NEC, ROP, days to full
      feeds, gastrointestinal perforation, length of stay, renal dysfunction defined by UOP &lt;
      1cc/kg/hr in an 8 hour period, creatinine elevation greater than 1.5 mg/dL, and discharge
      disposition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful treatment of PDA closure</measure>
    <time_frame>Follow-up ECHO to assess for closure within 7 days of treatment initiation</time_frame>
    <description>Definition of successful treatment of PDA is the PDA no longer meets the echocardiogram inclusion criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PDA retreatment</measure>
    <time_frame>1 year</time_frame>
    <description>Did the patient require a second course of treatment with either indomethacin or acetaminophen. Did the PDA require surgical closure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplement O2 requirement at 36 weeks PMA</measure>
    <time_frame>Until 36 weeks PMA</time_frame>
    <description>Was infant on &gt;21% O2 at 36 weeks post-menstrual age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nectrotizing enterocolitis</measure>
    <time_frame>1 year</time_frame>
    <description>As defined by Bell's Staging criteria, at any time during hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal perforation</measure>
    <time_frame>1 year</time_frame>
    <description>As defined by xray demonstration of free peritoneal air or as diagnosed by surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Death before discharge from NICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on invasive mechanical ventilation</measure>
    <time_frame>1 year</time_frame>
    <description>Days on invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on supplement oxygen</measure>
    <time_frame>1 year</time_frame>
    <description>Days on supplement oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to full feeds</measure>
    <time_frame>1 year</time_frame>
    <description>Day till the infant reaches 120 kcal/kg/d</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>1 year</time_frame>
    <description>Time from NICU admission to NICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of prematurity</measure>
    <time_frame>1 year</time_frame>
    <description>Stage of ROP and if any treatment was needed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine elevation greater than 1.5 mg/dL</measure>
    <time_frame>1 year</time_frame>
    <description>Creatinine elevation greater than 1.5 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Indomethacin as drug to treat PDA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetaminophen as drug to treat PDA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>IV indomethacin will be given every 12 hours for 3 doses. If &lt;48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If &gt;7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.</description>
    <arm_group_label>Indomethacin</arm_group_label>
    <other_name>Indocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>15mg/kg/dose every 6 hours for 12 doses</description>
    <arm_group_label>Acetaminophen</arm_group_label>
    <other_name>Ofirmev</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age at birth 22 weeks to 31 6/7 weeks.

          -  Birth weight ≤ 1500 grams

          -  Day of life ≤ 21 days

          -  ECHO findings:

        Left-to-right ductal flow AND 2 of the following 3:

          -  Ductal size &gt; 1.5mm at smallest diameter

          -  Reversal of flow in descending aorta

          -  Left atrial size to aortic root ratio &gt;1.5

          -  Platelet count &gt; 50,000

        Exclusion Criteria:

          -  Ductal dependent congenital heart disease

          -  Major congenital anomaly

          -  Life-threatening infection

          -  Urine output &lt; 1cc/kg/hr in prior 8 hours

          -  Serum creatinine &gt; 1.8 mg/dL

          -  Hyperbilirubinemia requiring exchange transfusion

          -  Active NEC Stage 2 or 3 using Bell's staging criteria

          -  Active intestinal perforation

          -  Liver dysfunction [2x upper limit of normal for aspartate aminotransferase(AST) and/or
             alanine aminotransferase (ALT)]

          -  Active GI bleeding

          -  Concurrent hydrocortisone use

          -  Known IVH Grade 3 or 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John M Ferguson, MD</last_name>
    <phone>901-448-6575</phone>
    <email>jfergu13@uthsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer M Hendrick, DO</last_name>
    <phone>901-448-8459</phone>
    <email>jhendr20@uthsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LeBonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M Hendrick, DO</last_name>
      <phone>901-448-8456</phone>
      <email>jhendr20@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>John M Ferguson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer M Hendrick, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist-Lebonheur Germantown Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth L Ivey, NNP-BC</last_name>
      <phone>901-516-6433</phone>
      <email>eivey@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Martin B Jenkins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional One Health</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M Hendrick, MD</last_name>
      <phone>901-448-8459</phone>
      <email>jhendr20@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>John M Ferguson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer M Hendrick, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011 Dec;128(6):e1618-21. doi: 10.1542/peds.2011-0359. Epub 2011 Nov 7.</citation>
    <PMID>22065264</PMID>
  </results_reference>
  <results_reference>
    <citation>Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013 Nov 4;8(11):e77888. doi: 10.1371/journal.pone.0077888. eCollection 2013.</citation>
    <PMID>24223740</PMID>
  </results_reference>
  <results_reference>
    <citation>Nadir E, Kassem E, Foldi S, Hochberg A, Feldman M. Paracetamol treatment of patent ductus arteriosus in preterm infants. J Perinatol. 2014 Oct;34(10):748-9. doi: 10.1038/jp.2014.96. Epub 2014 May 22.</citation>
    <PMID>24854626</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain A, Shah PS. Diagnosis, Evaluation, and Management of Patent Ductus Arteriosus in Preterm Neonates. JAMA Pediatr. 2015 Sep;169(9):863-72. doi: 10.1001/jamapediatrics.2015.0987. Review.</citation>
    <PMID>26168357</PMID>
  </results_reference>
  <results_reference>
    <citation>Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, Dilmen U. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. 2013;103(3):166-9. doi: 10.1159/000345337. Epub 2012 Dec 19.</citation>
    <PMID>23258386</PMID>
  </results_reference>
  <results_reference>
    <citation>EL-Khuffash A, James AT, Cleary A, Semberova J, Franklin O, Miletin J. Late medical therapy of patent ductus arteriosus using intravenous paracetamol. Arch Dis Child Fetal Neonatal Ed. 2015 May;100(3):F253-6. doi: 10.1136/archdischild-2014-307930. Epub 2015 Feb 4.</citation>
    <PMID>25653299</PMID>
  </results_reference>
  <results_reference>
    <citation>Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr. 2011 Apr;158(4):549-554.e1. doi: 10.1016/j.jpeds.2010.10.008. Epub 2010 Nov 20. Erratum in: J Pediatr. 2012 Jan;160(1):181.</citation>
    <PMID>21094951</PMID>
  </results_reference>
  <results_reference>
    <citation>Evans N, Malcolm G, Osborn D, Kluckow M. Diagnosis of patent ductus arteriosus in preterm infants. Neonatal Rev 2004; 5: e86-e97.</citation>
  </results_reference>
  <results_reference>
    <citation>Silverman NH, Lewis AB, Heymann MA, Rudolph AM. Echocardiographic assessment of ductus arteriosus shunt in premature infants. Circulation. 1974 Oct;50(4):821-5.</citation>
    <PMID>4418268</PMID>
  </results_reference>
  <results_reference>
    <citation>Ellison RC, Peckham GJ, Lang P, Talner NS, Lerer TJ, Lin L, Dooley KJ, Nadas AS. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics. 1983 Mar;71(3):364-72.</citation>
    <PMID>6338474</PMID>
  </results_reference>
  <results_reference>
    <citation>Dash SK, Kabra NS, Avasthi BS, Sharma SR, Padhi P, Ahmed J. Enteral paracetamol or Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonates: A Randomized Controlled Trial. Indian Pediatr. 2015 Jul;52(7):573-8.</citation>
    <PMID>26244949</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomson Reuters. Neofax 2011. Montvale, NJ: Thomson Reuters; 2011.</citation>
  </results_reference>
  <results_reference>
    <citation>Martin, R. J., Fanaroff, A. A., &amp; Walsh, M. C. (2015). Fanaroff and Martin's neonatal-perinatal medicine: Diseases of the fetus and infant (10th ed.). St. Louis, Mo.: Mosby/Elsevier</citation>
  </results_reference>
  <results_reference>
    <citation>Clyman, R. Patent Ductus Arteriosus in the Preterm Infant. in: C.A. Gleason, SU Devaskar (Eds.) Avery's disease of the newborn.9th ed.WB Saunders, Philadelphia;2012:751-761.</citation>
  </results_reference>
  <results_reference>
    <citation>Terrin G, Conte F, Oncel MY, Scipione A, McNamara PJ, Simons S, Sinha R, Erdeve O, Tekgunduz KS, Dogan M, Kessel I, Hammerman C, Nadir E, Yurttutan S, Jasani B, Alan S, Manguso F, De Curtis M. Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2016 Mar;101(2):F127-36. doi: 10.1136/archdischild-2014-307312. Epub 2015 Aug 17. Review.</citation>
    <PMID>26283668</PMID>
  </results_reference>
  <results_reference>
    <citation>Palmer GM, Atkins M, Anderson BJ, Smith KR, Culnane TJ, McNally CM, Perkins EJ, Chalkiadis GA, Hunt RW. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth. 2008 Oct;101(4):523-30. doi: 10.1093/bja/aen208. Epub 2008 Jul 15.</citation>
    <PMID>18628265</PMID>
  </results_reference>
  <results_reference>
    <citation>Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-3730. Epub 2015 Dec 15.</citation>
    <PMID>26672023</PMID>
  </results_reference>
  <results_reference>
    <citation>Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983 Jun;102(6):895-906.</citation>
    <PMID>6343572</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patent ductus arteriosus</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>indomethacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

